Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 6/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16380096 | 0.91 | PAK4 (0.54) | PAK4NAMPTPAK1HRH3CNR1 | |
| SCHEMBL18325909 | 0.91 | PAK4 (0.55) | PAK4NAMPTPAK1HRH3FASN | |
| SCHEMBL18325907 | 0.90 | PAK4 (0.53) | PAK4NAMPTPAK1HRH3CNR1 | |
| SCHEMBL18325901 | 0.90 | PAK4 (0.61) | PAK4NAMPTPAK1HRH3FASN | |
| SCHEMBL18325915 | 0.89 | PAK4 (0.53) | PAK4NAMPTPAK1HRH3CNR1 | |
| SCHEMBL18325912 | 0.88 | PAK4 (0.52) | PAK4NAMPTPAK1HRH3FASN | |
| SCHEMBL18325900 | 0.87 | PAK4 (0.53) | PAK4NAMPTPAK1MEN1KMT2A | |
| SCHEMBL18325911 | 0.86 | PAK4 (0.54) | PAK4NAMPTPAK1HRH3MEN1 | |
| SCHEMBL18325886 | 0.86 | PAK4 (0.51) | PAK4NAMPTPAK1FASN | |
| SCHEMBL18325917 | 0.86 | PAK4 (0.52) | PAK4NAMPTPAK1HRH3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2007/4885NAMPT 1663/4885PAK1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.